FDA Accepts NDA for Brain Cancer Imaging Agent TLX101-Px (Pixclara®), Sets September PDUFA Date

summarizeSummary

The FDA has accepted Telix's resubmitted New Drug Application for TLX101-Px (Pixclara®), an imaging agent for brain cancer, and set a PDUFA goal date of September 11, 2026.

check_boxKey Events

• NDA Accepted for TLX101-Px (Pixclara®)

  The FDA has accepted Telix's resubmitted New Drug Application for TLX101-Px, an investigational PET agent for imaging glioma (brain cancer).

• PDUFA Goal Date Set

  The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for potential approval.

• Addresses Unmet Medical Need

  TLX101-Px is intended to characterize recurrent or progressive glioma, a significant unmet medical need, and holds Orphan Drug and Fast Track designations.

• Potential Upside to Guidance

  Telix's current FY 2026 financial guidance does not include any revenue contribution from TLX101-Px, suggesting potential upside upon approval.

auto_awesomeAnalysis

The FDA's acceptance of the New Drug Application (NDA) for TLX101-Px (Pixclara®) is a significant de-risking event for Telix Pharmaceuticals. This investigational PET agent, designed for imaging glioma (brain cancer), addresses a critical unmet medical need and has previously received Orphan Drug and Fast Track designations. The assignment of a PDUFA goal date of September 11, 2026, provides a clear timeline for a potential regulatory decision, which could unlock a new revenue stream. Notably, Telix's current FY 2026 financial guidance does not factor in any revenue from TLX101-Px, indicating that a potential approval and subsequent commercialization could represent significant upside to existing expectations.